Should I buy or sell Artivion stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Artivion in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AORT shares. View AORT analyst ratings or view top-rated stocks .

What is Artivion's stock price target for 2024?

1 analysts have issued 12 month price targets for Artivion's shares. Their AORT share price targets range from $22.00 to $22.00. On average, they expect the company's share price to reach $22.00 in the next year. This suggests a possible upside of 23.0% from the stock's current price. View analysts price targets for AORT or view top-rated stocks among Wall Street analysts .

How have AORT shares performed in 2023?

Artivion's stock was trading at $12.12 at the beginning of the year. Since then, AORT stock has increased by 47.5% and is now trading at $17.88. View the best growth stocks for 2023 here .

Are investors shorting Artivion?

Artivion saw a increase in short interest during the month of December. As of December 15th, there was short interest totaling 3,140,000 shares, an increase of 5.0% from the November 30th total of 2,990,000 shares. Based on an average daily volume of 234,200 shares, the days-to-cover ratio is currently 13.4 days. Approximately 8.1% of the company's shares are short sold. View Artivion's Short Interest .

When is Artivion's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 15th 2024. View our AORT earnings forecast .

How were Artivion's earnings last quarter?

Artivion, Inc. (NYSE:AORT) released its quarterly earnings results on Thursday, November, 2nd. The company reported $0.02 earnings per share for the quarter, beating analysts' consensus estimates of $0.01 by $0.01. The business had revenue of $87.85 million for the quarter, compared to the consensus estimate of $85.65 million. Artivion had a positive trailing twelve-month return on equity of 2.88% and a negative net margin of 7.23%.

What guidance has Artivion issued on next quarter's earnings?

Artivion updated its FY 2023 earnings guidance on Friday, December, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $349.0 million-$351.0 million, compared to the consensus revenue estimate of $349.6 million.

How do I buy shares of Artivion?

Shares of AORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:AORT

Artivion (AORT) Stock Price, News & Analysis

$17.88

-0.34 (-1.87%)

(As of 12/29/2023 ET)

Compare

Today's Range: $17.78
▼
$18.25
50-Day Range: $12.34
▼
$18.83
52-Week Range: $11.44
▼
$19.00

Volume: 173,100 shs
Average Volume: 220,196 shs
Market Capitalization: $733.08 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $22.00

Artivion MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 23.0% Upside
$22.00 Price Target
Short Interest: Bearish
8.06% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$309,974 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.04) to $0.01 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.44 out of 5 stars

Medical Sector

891st out of 950 stocks

Surgical & Medical Instruments Industry

89th out of 92 stocks

2.5

Analyst's Opinion

Consensus Rating
Artivion has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $22.00, Artivion has a forecasted upside of 23.0% from its current price of $17.88.
Amount of Analyst Coverage
Artivion has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
8.06% of the float of Artivion has been sold short.
Short Interest Ratio / Days to Cover
Artivion has a short interest ratio ("days to cover") of 13.4, which indicates bearish sentiment.
Change versus previous month
Short interest in Artivion has recently increased by 5.02%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Artivion does not currently pay a dividend.
Dividend Growth
Artivion does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AORT.

1.7

News and Social Media Coverage

News Sentiment
Artivion has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Artivion this week, compared to 1 article on an average week.
Search Interest
9 people have searched for AORT on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.
MarketBeat Follows
3 people have added Artivion to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Artivion insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $309,974.00 in company stock.
Percentage Held by Insiders
Only 6.60% of the stock of Artivion is held by insiders.
Percentage Held by Institutions
83.32% of the stock of Artivion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Artivion are expected to grow in the coming year, from ($0.04) to $0.01 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Artivion is -29.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Artivion is -29.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Artivion has a P/B Ratio of 2.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Artivion Stock (NYSE:AORT)

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent and graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.

AORT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AORT Stock News Headlines

December 18, 2023 | finance.yahoo.com

Artivion, Inc. (NYSE:AORT) Soars 36% But It's A Story Of Risk Vs Reward

December 11, 2023 | finance.yahoo.com

Artivion, Inc. (NYSE:AORT) is a favorite amongst institutional investors who own 78%

December 31, 2023 | MarketBeat Internal (Ad)

New Year's Sale: Get MarketBeat All Access Free For 30 Days

Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Click the link to claim your $300.00 account credit and free 30-day subscription

December 8, 2023 | markets.businessinsider.com

Stifel Nicolaus Reaffirms Their Buy Rating on Artivion (AORT)

December 7, 2023 | msn.com

Artivion appoints Lance A. Berry as EVP, CFO; reaffirms FY23 outlook

December 6, 2023 | finance.yahoo.com

Artivion Appoints Lance A. Berry as Executive Vice President, Chief Financial Officer; Announces Retirement of D. Ashley Lee, Chief Financial Officer

November 21, 2023 | benzinga.com

A Congress Member Bought Up To $200K In Artivion Stock: Here's What You Need To Know

November 9, 2023 | finance.yahoo.com

Artivion Announces Completion of Enrollment in PERSEVERE Trial

December 31, 2023 | MarketBeat Internal (Ad)

New Year's Sale: Get MarketBeat All Access Free For 30 Days

November 5, 2023 | seekingalpha.com

Artivion, Inc. 2023 Q3 - Results - Earnings Call Presentation

November 2, 2023 | ca.finance.yahoo.com

Artivion Inc (AORT) Reports 14% Revenue Growth in Q3 2023

November 2, 2023 | finance.yahoo.com

Artivion Reports Third Quarter 2023 Financial Results

November 2, 2023 | msn.com

Artivion (AORT) Price Target Increased by 5.86% to 25.81

October 19, 2023 | finance.yahoo.com

Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2023 Financial Results

October 13, 2023 | seekingalpha.com

Artivion's Ongoing Clinical Studies Could Drive Significant Growth Starting In 2025

October 7, 2023 | hk.finance.yahoo.com

Investors in Artivion (NYSE:AORT) have unfortunately lost 50% over the last five years

October 7, 2023 | markets.businessinsider.com

Promising Clinical Outcomes and Growth Potential Drive Buy Rating for Artivion

October 5, 2023 | finance.yahoo.com

Artivion Announces Presentation of Late-Breaking Interim Data from AMDS PERSEVERE Trial at the 37th European Association for Cardio-Thoracic Surgery Annual Meeting

October 5, 2023 | finance.yahoo.com

Artivion Announces Presentation of Real World Data from Post Market Study of On-X® Aortic Heart Valve Replacement Patients Treated with Low Dose Warfarin

September 26, 2023 | finance.yahoo.com

Artivion to Present at the Deutsche Bank 31st Annual Leveraged Finance Conference

August 31, 2023 | finance.yahoo.com

Wall Street Analysts Believe Artivion (AORT) Could Rally 44.41%: Here's is How to Trade

August 10, 2023 | finance.yahoo.com

Does Artivion (AORT) Have the Potential to Rally 52.78% as Wall Street Analysts Expect?

August 3, 2023 | msn.com

Artivion (AORT) Q2 Earnings and Revenues Top Estimates

August 3, 2023 | finance.yahoo.com

Artivion Reports Second Quarter 2023 Financial Results

August 2, 2023 | benzinga.com

Earnings Preview: Artivion

July 28, 2023 | finance.yahoo.com

The Return Trends At Artivion (NYSE:AORT) Look Promising

July 20, 2023 | finance.yahoo.com

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2023 Financial Results

See More Headlines

Receive AORT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Artivion and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/02/2023
Today: 12/31/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/15/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:AORT
CUSIP: N/A
CIK: 784199
Web: www.cryolife.com
Phone: (770) 419-3355
Fax: 770-426-0031
Employees: 1,300
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $22.00
High Stock Price Target: $22.00
Low Stock Price Target: $22.00
Potential Upside/Downside: +23.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.60)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-19,190,000.00
Net Margins: -7.23%
Pretax Margin: -5.22%
Return on Equity: 2.88%
Return on Assets: 1.05%

Debt

Debt-to-Equity Ratio: 1.14
Current Ratio: 4.86
Quick Ratio: 3.43

Sales & Book Value

Annual Sales: $313.79 million
Price / Sales: 2.34
Cash Flow: $0.61 per share
Price / Cash Flow: 29.42
Book Value: $7.05 per share
Price / Book: 2.54

Miscellaneous

Outstanding Shares: 41,000,000
Free Float: 38,294,000
Market Cap: $733.08 million
Optionable: Optionable
Beta: 1.54

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. James Patrick Mackin (Age 56)
Chairman, President & CEO
Comp: $1.63M
Ms. Jean F. Holloway Esq. (Age 66)
Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary
Comp: $636.72k
Mr. John E. Davis (Age 58)
Senior Vice President of Global Sales & Marketing
Comp: $609.91k
Dr. Marshall S. Stanton M.D. (Age 66)
Senior VP of Clinical Research & Chief Medical Officer
Comp: $615.55k
Mr. Lance E. Berry CPA (Age 51)
Executive VP & CFO
Ms. Amy D. Horton CPA (Age 53)
VP & Chief Accounting Officer
Mr. Matthew A. Getz (Age 53)
VP & Chief Human Resources Officer
Robert C. Thomson
VP of Research & Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AORT Stock Analysis - Frequently Asked Questions

Should I buy or sell Artivion stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Artivion in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AORT shares.
View AORT analyst ratings or view top-rated stocks.
What is Artivion's stock price target for 2024?: 1 analysts have issued 12 month price targets for Artivion's shares. Their AORT share price targets range from $22.00 to $22.00. On average, they expect the company's share price to reach $22.00 in the next year. This suggests a possible upside of 23.0% from the stock's current price.
View analysts price targets for AORT or view top-rated stocks among Wall Street analysts.
How have AORT shares performed in 2023?: Artivion's stock was trading at $12.12 at the beginning of the year. Since then, AORT stock has increased by 47.5% and is now trading at $17.88.
View the best growth stocks for 2023 here.
Are investors shorting Artivion?: Artivion saw a increase in short interest during the month of December. As of December 15th, there was short interest totaling 3,140,000 shares, an increase of 5.0% from the November 30th total of 2,990,000 shares. Based on an average daily volume of 234,200 shares, the days-to-cover ratio is currently 13.4 days. Approximately 8.1% of the company's shares are short sold.
View Artivion's Short Interest.

When is Artivion's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 15th 2024.
View our AORT earnings forecast.
How were Artivion's earnings last quarter?: Artivion, Inc. (NYSE:AORT) released its quarterly earnings results on Thursday, November, 2nd. The company reported $0.02 earnings per share for the quarter, beating analysts' consensus estimates of $0.01 by $0.01. The business had revenue of $87.85 million for the quarter, compared to the consensus estimate of $85.65 million. Artivion had a positive trailing twelve-month return on equity of 2.88% and a negative net margin of 7.23%.
What guidance has Artivion issued on next quarter's earnings?: Artivion updated its FY 2023 earnings guidance on Friday, December, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $349.0 million-$351.0 million, compared to the consensus revenue estimate of $349.6 million.
How do I buy shares of Artivion?: Shares of AORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:AORT) was last updated on 12/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial